Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections
摘要:
Rhinovirus (genus enterovirus) infections are responsible for many of the severe exacerbations of asthma and chronic obstructive pulmonary disease. Other members of the genus can cause life-threatening acute neurological infections. There is currently no antiviral drug approved for the treatment of such infections. We have identified a series of potent, broad-spectrum antiviral compounds that inhibit the replication of the human rhinovirus, Coxsackie virus, poliovirus, and enterovirus-71. The mechanism of action of the compounds has been established as inhibition of a lipid kinase, PI4KIII beta. Inhibition of hepatitis C replication in a replicon assay correlated with enterovirus inhibition.
Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.
Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections
申请人:MacLeod Angus
公开号:US08362018B2
公开(公告)日:2013-01-29
Novel imidazopyrazine compounds are disclosed that have a formula represented by the following:
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.
Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis
申请人:Biofocus DPI Limited
公开号:EP2567960A2
公开(公告)日:2013-03-13
Novel imidazopyrazine compounds are disclosed that have a formula represented by the following:
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.